JPRN-UMIN000011411招募中2 期
Phase II study of Erlotinib monotherapy in EGFR mutation-negative lung adenocarcinoma excluded biomarkers against EGFR-TKI treatment. - FONTANA
Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicine0 个研究点目标入组 23 人开始时间: 2013年8月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis 2) Patients with activating EGFR mutation or EML4-ALK fusion gene or K-Ras mutation or MET protein over expression 3) Patients with no history of chemotherapy for lung cancer 4) Patients with uncontrolled ascites, pleural effusion, or pericardial effusion 5) Patients with active severe infections 6) Patients with past history of administration of HER related agents 7) Impossible cases with oral administration 8) Patients with active ophthalmological disease 9) Pregnancy, breast feeding and suspected pregnancy 10) Patients with symptomatic brain metastasis 11) Patients with double cancer 12) Patients with uncontrollable diabetes mellitus 13) Patients with uncontrollable complications 14) Inappropriate patients for this study judged by the physicians
研究者
相似试验
进行中（未招募）
1 期
Erlotinib treatment beyound progressioocally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor or who have responded to EGFR TKIMedDRA version: 14.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2013-002049-13-FIOulu University Hospital
已完成
不适用
A phase II study of erlotinib for gefitinib-resistant non-small cell lung cancer without T790M mutation analyzed in the circulating tumor cellon-small cell lung cancerJPRN-UMIN000004046orth-East Japan Study Group20
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
已完成
2 期
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7
已完成
2 期
Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304)JPRN-UMIN000011473OSAKA-LCSG23